Company Updates

Vita Imaging Company Update

In this company update, we look at Vita Imaging announcing a new crowdfunding round on Dealmaker at a $40.1M valuation, reflecting its progress in FDA approval and current financial situation.

Funding Round Details

Vita Imaging logo
Company: Vita Imaging
Security Type: Equity - Common
Valuation: $40,100,000
Min Investment: $570
Platform: Dealmaker Securities
Deadline: Apr 28, 2024
$4,120,000
View Deal
  • Vita Imaging has opened a new round on Dealmaker Securities at a valuation of $40.1M, up just 0.4% from its 2023 round of $39.94M.
  • The most important change to consider in this round is that the company indicated its target FDA approval by the end of 2023. In this round, the company states that “FDA review is in its final stages and targeted for completion in 2024.” 
  • While timeline changes are common for Medical Technology companies seeking FDA approval, Vita has not addressed the reason for this delay. 
  • While the company did not produce updated financial statements, buried in the Form C is the following statement:

“As of December 31, 2023, the Company had $121,806 cash on hand. In addition, as of December 31, 2023, the Company has approximately $404,411 of unused credit pursuant to a $1.5 million convertible line of credit with the founder and CEO Mr. Thinh Tran. If the Company raises the minimum Offering Amount of $15,000, then management anticipates that the cash on hand and line of credit are sufficient to fund the next eight months of operation. If the Company raises the Maximum amount of the Offering, $4,120,000 then management anticipates that the cash on hand and line of credit are sufficient for the next three years. 

We believe the funds from this campaign are critical to our operations. These funds are required to support the Aura product’s existing FDA clearance application and build enough units to begin sales and marketing.”

Read the full offering circular HERE.

  • This indicates that the company needs a capital infusion, given that it ran at a loss of—$837,822 and—$1,112.284 in 2022 and 2021, respectively. While we don’t know what the loss was in 2023, we can assume it was around these figures and that the current cash on hand is insufficient to get the product to commercialization.

Teddy Lyons
About: Teddy Lyons

Teddy comes to KingsCrowd with a background in venture capital and investment banking. He worked at Deutsche Bank as an Investment Banking Analyst in the Technology, Media, and Telecommunications group. Prior to that, he served as an Associate at Alchemi Capital, a venture capital firm in Boston that invests in early-stage technology companies. Teddy holds a degree in Economics and Psychology from Wesleyan University, where he was captain of the varsity soccer team. He also holds a M.S. in Finance from Boston College.


Recent Posts

Avoid Startup Investing Tax Surprises

Understand when your startup investments might trigger taxes. Learn about liquidity events, losses, and other tax implications of investing in startups.

Brian Belley
Brian Belley Apr 14, 2024
Education
Avoid Startup Investing Tax Surprises

Investment Crowdfunding Exits: How Long Will You Wait?

Analyzing the average time to exit or failure (i.e. holding period) for investment crowdfunding companies since 2016.

Brian Belley
Brian Belley Apr 14, 2024
Industry Analysis
Investment Crowdfunding Exits: How Long Will You Wait?

Q1 Overview: Key Takeaways from Online Private Market Investments

First Quarter Trends in Online Investing in 2024

Olivia Strobl
Olivia Strobl Apr 8, 2024
Industry Analysis
Q1 Overview: Key Takeaways from Online Private Market Investments

Give your startup investing an edge by creating a free KingsCrowd account and getting started today.

Get a free weekly Pitch Review!

Sign up for our 3 minute newsletter with fresh takes on the top-rated investments and key startup trends you should know.

We care about the protection of your data. Read our Privacy Policy.